Adoprazine

Adoprazine (SLV313) is a full 5-HT1A receptor agonist with a pEC50 of 9 at cloned h5-HT1A receptors. Adoprazine (SLV313) is a full D2 and D3 receptor antagonist with pA2s of 9.3 and 8.9 at hD2 and hD3 receptors, respectively. Adoprazine (SLV313) has the characteristics of atypical antipsychotics[1].

Product Specifications

CAS Number

[222551-17-9]

Product Name Alternative

SLV313

UNSPSC

12352005

Target

5-HT Receptor; Dopamine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Adoprazine.html

Concentration

10mM

Purity

98.60

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

FC1=CC=C(C2=CN=CC(CN3CCN(C4=C5OCCOC5=CC=C4)CC3)=C2)C=C1

Molecular Formula

C24H24FN3O2

Molecular Weight

405.46

References & Citations

[1]Andrew C McCreary, et al. SLV313 (1- (2,3-dihydro-benzo[1,4]dioxin-5-yl) -4- [5- (4-fluoro-phenyl) -pyridin-3-ylmethyl]-piperazine monohydrochloride) : a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug. Neuropsychopharmacology. 2007 Jan;32 (1) :78-94.|[2]Liesbeth A Bruins Slot, et al. Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase. Eur J Pharmacol. 2006 Mar 18;534 (1-3) :63-70.